Curriculum Vitae PERSONAL INFORMATION Massimo Federico WORK EXPERIENCE May 2005–Present Director, Medical Oncology University of Modena and Reggio Emilia, (Italy) Director of the Medical Oncology and Lymphoma Unit at Modena Cancer Center, Modena, Italy, as well as Director of the Modena Cancer Registry (Registro Tumori di Modena) and President of the Angela Serra Association for Cancer Research (Associazione Angela Serra per la ricerca sul cancro). Related document(s): EDUCATION AND TRAINING May 2005–Present Professor of Medical Oncology University of Modena and Reggio Emilia, (Italy) Professor Federico graduated from medical school in 1974 and was then faced with the decision of choosing a subspeciality. He selected a 3-year hematology post-graduate course at the University of Modena and, after it concluded in 1977 undertook a 5-year program on internal medicine at the University of Pavia. Dr Federico is board-certified in hematology and internal medicine. After working in the department of internal medicine in Modena, he moved to the new area of medical oncology. Professor Federico is now Professor of Medical Oncology at the University of Modena and Reggio Emilia, Modena, Italy, and Director of the Medical Oncology and Lymphoma Unit at Modena Cancer Center, Modena, Italy, as well as Director of the Modena Cancer Registry (Registro Tumori di Modena) Related document(s): ADDITIONAL INFORMATION Expertise Prof. Federico has a board range of transational scientific and clinical interests, spanning cancer epidemiology, hereditary breast cancer, design and conduction of clinical trials, and clinical management of lymphomas (including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and hairy cell leukemia) and breast cancer. He has published in all of this area as author or co-author of over 400 articles (more than 280 on PubMed), most of them in peer-reviewed journals. As a Director of Modena Cancer Registry has published several Monographies on cancer epidemiology in the Province of Modena for the years 1988-2011. Professor Federico’s clinical research career began during the postgraduate hematology program in Modena. In 1976 he first joined the team to investigate the role of allogenic stem cell transplantation in homozygous twins. In 1988 and the in 1989, Professor Federico went to the US as Visiting Research Associate at the Department of Electrical and Computer Engineering, Bioacustic Research Laboratory of the University of Illinois (Urbana, Illinois). He worked in basic research with a group of biophysicists involved in research on improving the role of bone marrow imaging then MRI. In 1993, Professor Federico went to the US for his second sabbatical as Visiting Research Associate, this time at the Arizona Cancer Center of the University of Arizona, Tucson. His work was split between the development of smarter strategies and designs for controlled clinical trials, better analysis of clinical data, expertise in biostatistics and data analysis and interpretation, and investigating the role of in vitro testing of new drugs for advanced ovarian cancer, an area of specialized research for the Center. Back in Italy in December 1995, he continued his work on lymphoma research in Modena. Currently he is spending a third sabbatical as visiting professor at University of Salento, Lecce, promoting the growth of an area of excellence in the field of clinical research at UNISALENTO. The most important work done by Professor Federico in the last 20 years was investigating prognostic factors in different lymphomas, including Hodgkin Lymphoma (HL), follicular lymphoma (FL), Peripheral T Cell Lymphoma (PTCL), and Splenic Marginal Zone Lymphoma (SMZL) . At the 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 1 / 20 Curriculum Vitae Massimo Federico beginning, the most relevant contribution was investigating the prognosis of HL, then moving to FL, SMZL, and eventually PTCL, with the aim to help in choosing more appropriate treatments for affected patients. He has conducted several phase II and III clinical trials comparing different treatment strategies for HL, DLBCL, Indolent lymphoma, and FL. Publications 14) Gobbi P.G., Cavalli P., Franzini B., Di Prisco A.U., Federico M., Bonacorsi G.: Tonsillectomy: a prognostic factor in Hodgkin’s disease? Tumori 67:425-430, 1981. 19) Artusi T., Saragoni A., Bonacorsi G., Di Prisco A.U., Spedicato M., Silingardi V., Federico M.: Castleman’s lymphoadenopathy: twenty years of observation. I. General considerations. Monoadenopathic variety. Haematologica 67:109-123, 1982. 20) Artusi T., Bonacorsi G., Saragoni A., Spedicato M., Rinaldi G., Federico M., Silingardi V.: Castleman’s lymphoadenopathy. II. Generalized form. Haematologica 67:124-142, 1982. 26) Gobbi P.G., Attardo Parrinello G., Di Prisco A.U., Federico M., Bonacorsi G., Dini D., Marabelli S., Rizzo S.C., Ascari E.: New clinical criteria for the assessment of liver involvement in Hodgkin’s disease. Eur. J. Cancer Clin. Oncol. 18:1243-1249, 1982. 40) Federico M., Barbieri F., Dini D., Bonacorsi G., Fontana G., Rinaldi G., Artusi T., Silingardi V.: A report of seven long survivors for evidence of prognostic factors in hairy cell leukemia. Tumori 70:518-521, 1984. 41) Gobbi PG., Gendarini A., Crema A., Cavalli C., Attardo Parrinello G., Federico M., Di Prisco AU., Ascari E. Serum albumin in Hodgkin’s disease. Cancer 55:389-93, 1985. 50) Gobbi PG., Cavalli C., Gendarini A., Crema A., Ricevuti G., Federico M., Di Prisco AU., Ascari E.: Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer 56:2874-2880, 1985. 51) Silingardi V., Federico M., Barbieri F., Artusi T., Mauri C.: Hairy cell leukemia: a reversible disease? A report of two cases of spontaneous remission. Haematologica 5:437-441, 1985. 67) Damasio EE., Bernasconi C., Castoldi GL., Chisesi T., Federico M., Lamparelli T., Lauria F., Pagnucco G., Resegotti L., Rossi E.: Human Lymphoblastoid interferon for HCL: results from the Italian Cooperative Group. Leukemia 1:331-33, 1987. 76) Gobbi GP., Cavalli C., Federico M., Bertoloni D., Di Prisco AU., Rossi A., Silingardi V., Mauri C., Ascari A.: Hodgkin’s disease prognosis: a directly predictive equation. Lancet 675-679, 1988. 90) Silingardi V., Davolio Marani S., Federico M., Piccinini L., Frassoldati A., Sarti M., Burani A., Canossi GC.: Bone marrow infiltration in Hairy cell leukemia after Interferon therapy detected by magnetic resonance imaging. Eur. J. Cancer Clin. Oncol., 25:209-213, 1989. 92) Gobbi GP., Cavalli C., Federico M., Lombardo M., Bertoloni D., Grignani GE., Pieresca C., Ascari A., Mauri C.: Increasing interdependency of prognosis and therapy-related factors in Hodgkin’s disease. Acta Haematol. 81:34-40, 1989. 101) Damasio E.E., Pagnucco G., Federico M., Annino L., Chisesi T., Lamparelli T., Lauria F., Castoldi GL., Resegotti L.: Hairy Cell Leukemia. A therapeutical update. Haematologica 74:205-218, 1989. 102) Federico M., Iannone A., Chan H.C., Magin RL.: Bone Marrow Uptake of Liposome-Entrapped Spin Label after Liver Blockade with Empty Liposomes. Magnetic Resonance in Medicine. 10:418-425, 1989. 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 2 / 20 Curriculum Vitae Massimo Federico 104) Federico M., Chisesi T., Lauria F., Bernasconi C., Capnist G., Castoldi G., Damasio EE., Pagnucco G., Frassoldati A., Resegotti L., Silingardi V.: Human Lymphoblastoid interferon as initial therapy in hairy cell leukemia: a multicenter study in non-splenectomized patients. Brit. J. Haematol., 72:54-56, 1989. 105) Federico M., Magin RL., Swartz HM., Wright RM., Silingardi V.: Detection of bone marrow involvement in patients with cancer. Tumori, 75:90-96, 1989. 125) Silingardi V., Federico M., Frassoldati A., Barbieri F., Palomba G., Mauri C.: Free from failure survival in Hodgkin’s disease. Long term analysis of 148 cases treated with a MOPP modified protocol. Acta Haematol. 82:179-186, 1989. 126) Federico M., Gobbi PG., Barbieri F., Silingardi V. Relationship between prognostic factors and therapy in high grade non Hodgkin’s lymphomas over two decades. Haematologica 74:511-519, 1989. 153) Ferrari P., Federico M., Grimaldi L.M.E., Silingardi V.: Stiff-man syndrome in a patient with Hodgkin’s disease. An unusual paraneoplastic syndrome. Haematologica, 75:570-572, 1990. 164) Torelli G., Marasca R., Luppi M., Selleri L., Ferrari M., Narni F., Mariano M.T., Federico M., Ceccherini Nelli L., Bendinelli M., Montagnani G., Montorsi M., Artusi T.: Human Herpes Virus-6 in human lymphomas: identification of specific sequences in Hodgkin’s lymphomas by Polimerase Chain Reaction. Blood 77:1-5, 1991. 166) Capnist G., Federico M., Chisesi T., Resegotti L., Pagnucco G., Castoldi G.L., Lamparelli T., Frassoldati A., Guarnaccia C., Leoni P., Fabris P., Rossi G., Invernizzi R., Ambrosetti A., Bernasconi C., Damasio E.: Should alpha interferon be used as primary treatmant for Hairy Cell Leukemia? Leukemia Research 15:419-426, 1991. 176) Iannone A., Magin R.L., Walczac T., Federico M., Swartz H.M., Tomasi A., Vannini V.: Blood clearance of dextran magnetite particles by a noninvasive in vivo ESR method. Magnetic Resonance in Medicine 22:435-442, 1991. 186) Cirillo M., Federico M., Curci G., Tamborrino E., Piccinini L., Silingardi V.: Primary gastro intestinal lymphoma: a clinico pathologic study of 58 cases. Haematologica 77:156-161, 1992. 192) Iannone A., Federico M., Tomasi A., Magin R.L., Casasco A., Calligaro A., Vannini V.: Detection and quantitation in rat tissues of the superparamagnetic MR contrast agent Dextran Magnetite as demonstrated by ESR spectroscopy. Investigative Radiology 27:450-455, 1992. 205) Gobbi P.G., Pieresca C., Federico M., Di Renzo N., Narni F., Iannitto V., Grignani G., Cavanna L., Avanzini P., Partesotti G., Pitini V., Ascari E., Silingardi V., Mauri C.: MOPP/EBV/CAD hybrid chemotherapy + limited radiotherapy in advanced or unfavorably presenting Hodgkin’s disease. J. Clin. Oncol. 11:712-719, 1993. 213) Brugiatelli M., Federico M., Gobbi P.G., Avanzini P., Callea V., Cavanna L., De Pasquale A., Di Prisco A.U., Di Renzo N., Silingardi V., Mauri C.: Epidoxorubicin vs Idarubicin containing regimens in intermediate and high grade non Hodgkin’s lymphoma: preliminary results of a multicentric randomized trial. Haematologica 78:306-312, 1993. 222) Frassoldati A., Lamparelli T., Federico M., Annino L., Capnist G., Pagnucco G., Resegotti L., Damasio E.E.: Hairy cell leukemia. A clinical review based on 725 cases of the italian cooperative group. Leukemia & Lymphoma 13:307-316, 1994. Guarnaccia C., Leoni P., Lauria F., Pagnucco G., Frassoldati A., Damasio E.: Long term results of interferon treatment in hairy cell leukemia. Leukemia and Lymphoma 14:457-464, 1994. 223) Capnist G., Federico M., Chisesi T., Resegotti L., Lamparelli T., Fabris P., Rossi G., Invernizzi R., Guarnaccia C., Leoni P., Lauria F., Pagnucco G., Frassoldati A., Damasio E.: Long term results of interferon treatment in hairy cell leukemia. 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 3 / 20 Curriculum Vitae Massimo Federico Leukemia & Lymphoma (ISSN 1042-8194) 14-457:464, 1994 224) Federico M., Frassoldati A., Lamparelli T., Foa’ R., Brugiatelli M., Annino L., Baldini L, Capnist G., Chisesi T., Francia di Celle P., Invernizzi R., Lauria F., Truini M., Resegotti L., Silingardi V., Damasio E.E. for the ICGHCL: Long term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian cooperative group for HCL Annals of Oncology, 5:725-731, 1994. 233) Silingardi V., Federico M., Cavanna L., Avanzini P., Gobbi P.G., Lombardo M., Carotenuto M., Frassoldati M., Pieresca C., Vallisa D., Merli F., Ascari E., Mauri M.: ProMECE-CytaBOM vs MACOPB in advanced aggressive non-Hodgkin’s lymphoma. Long-term results of a multicenter study of the Italian lymphoma study group (GISL). Leukemia and Lymphoma 17:313-320, 1995. 257) Sabbatini R., Federico M., Baldini L., Maiolo M.T., Silingardi V.: A randomised double-blind, cross-over study comparing levosulpiride-based with metoclopramide-based combination in the prevention of ProMECE-CytaBOM induced emesis. Haematologica, 80:416-420, 1995. 258) Longo G., Federico M., Pieresca C., Avanzini P., Iannitto E., Di Prisco A.U., Baldini L., Brugiatelli M., Clò V., Bevini M., Silingardi V.: Anaplastic large cell lymphoma. Analysis of 35 cases followed at GISL centers. Eur. J. Cancer, 31:1763-1767, 1995. 262) Gobbi P.G., Pieresca C., Frassoldati A., Carotenuto M., Di Renzo N., La Sala A., Bertè R., Federico M., Silingardi V., Ascari E. Vinblastine, bleomycin and methotrexate (VBM) chemotherapy plus extended field radiotherapy in early, favourably presenting, clinically staged Hodgkin’s patients: The gruppo Italiano per lo Studio dei Linfomi Experience J. Clin. Oncol, 14:527-533, 1996 263) Carella AM, Prencipe E, Pungolino E, Lerma E, Frassoni F, Rossi E, Giordano D, Occhini D, Gatti AM, Bruni R, Spriano M, Nati S, Pierluigi D, Congiu M, Vimercati R, Rovatti JL, Federico M. Twelve years experience with high dose therapy and autologous stem cell transplantation for high risk Hodgkin’s disease patients in first remission after MOPP/ABVD. Leukemia & Lymphoma 21:63-70, 1996. 274) Luppi M., Morselli M., Bandieri E., Federico M., Marasca R., Barozzi P., Ferrari M.G., Savarino M., Torelli G.: Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann. Oncol. 7:619-624,1996 279) Gobbi P.G., Pieresca C., Cavanna L., Corbella F., Vallisa D., Federico M., Formisano R., Carotenuto M., Merli F., Callea V., Angrilli F., Silingardi V.:CCNU, Vinblastine, Procarbazine and Prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgking’s disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Haematologica, 81: 503-512, 1996 286) Baldini L., Guffanti A., Gobbi P., Colombi M., Federico M., Avanzini P., Cavanna L., Pieresca C., Silingardi V., Maiolo A.T. for the Gruppo Italiano per lo Studio dei Linfomi (GISL): A pilot study on use of PROMACE-CYTABOM regimen as first line treatment in advanced follicular lymphoma. Cancer 79:1234-1240,1997 302) Iannitto E., Accurso V., Federico M., Vallisa D., Pieresca C., Gravina S.F., Di Costanzo F., Di Trapani R., Silingardi V., Mariani G.: Hodgkin’s disease presentig below the diaphragm. The experience of the Gruppo Italiano Studio Linfomi (GISL). Haematologica 82: 676-682, 1997. 309) Merli F., Federico M., Avanzini P., Ilariucci F., Stelitano C., Iannitto E., Colombi M., Vallisa D., Santagati G., Piccinini L.: Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Haematologica 83:217-221, 1998 310) Gobbi P.G., Pieresca C., Ghirardelli M.L., Di Renzo N., Federico M., Merli F., Iannitto E., Pitini V., Grignani G., Donelli A., Carotenuto M., Silingardi V., and Ascari E. for the Gruppo Italiano per lo Studio dei Linfomi: Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 91(8):2704-2712, 1998. 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 4 / 20 Curriculum Vitae Massimo Federico 322) Federico M., Clo' V., Brugiatelli M., Carotenuto M., Gobbi PG., Vallisa D., Lombardo M., Avanzini P., Di Renzo N., Dini D., Baldini L., Ginaldi L., Silingardi V., Mauri C.: Efficacy of two different ProMACE-CytaBOM derived regimens in Advanced Aggressive Non Hodgkin's Lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica,83:800-811,1998 328) Federico M., Maiorana A., Mangone L., Turchetti D., Canossi B., Cortesi L., Romagnoli R., Silingardi V.: Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance. The Modena Study Group proposal. Breast Cancer Research and Treatment 55:213-221, 1999. 330) Longo G., Fiorani C., Sacchi S., Callea V., Lombardo M., Federico M., Stelitano C., Angrilli F., Vallisa D., Gobbi P.G., Ilariucci F., Frassoldati A., Petrini M., Silingardi V. for the Gruppo Italiano per lo Studio dei Linfomi (GISL): Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Haematologica 84:425-430, 1999. 359) Cortesi L., Turchetti D., Bertoni C., Bellei R., Mangone L., Vincenti M., Federico M., Silingardi V., Ferrari S.: Comparison between genotype and phenotype identifies a high-risk population carrying BRCA I mutation. Genes, Chromosomes and Cancer, 27:130-135, 2000. 360) Federico M., Vitolo U., Zinzani P.L., Chisesi T., Clò V., Bellesi G., Magagnoli M., Liberati M., Boccomini C., Niscola P., Pavone V., Cuneo A., Santini G., Brugiatelli M., Baldini L., Rigacci L., Resegotti L. for the Intergruppo Italiano Linfomi: The prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases of the Italian Lymphoma Intergroup. Blood, 95:3,783-789, 2000. 361) Stelitano C., Baldini L., Pieresca C., Callea V., Angrilli F., Clo V., Partesotti G., Merli F., Cavanna L., Morabito F., Federico M., Brugiatelli M., Silingardi V.: Validation of the international prognostic index in working formulation group a low-grade non-Hodgkin’s lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo studio dei linfomi registry. Haematologica, 85:2,154-159, 2000. 375) Sabbatini R., Federico M., Depenni R., Morselli M., Cagossi K., Luppi M., Torelli G., Silingardi V.: Detection of circulating tumor cells in patients with breast cancer undergoing conventional-dose chemotherapy by RT-PCR of Maspin. Journal of Clinical Oncology, 18:9,1914-1920,2000. 379) Turchetti D., Cortesi L., Federico M., Bertoni C., Mangone L., Ferrari S., Silingardi V.: BRCA1 Mutations and clinicopathological features in a sample of italian women with early-onset breast cancer. European Journal of Cancer, 36-1-6:2083-2089,2000. 392) Sacchi S., Federico M., Dastoli G., Fiorani C., Vinci G., Clò V., Casolari B.: Treatment of B-cell low-grade non-Hodgkin’s lymphoma with anti CD 20 monoclonal antibody Rituximab. Critical Reviews in Oncology-Hematology, 37:13-25,2001. 392) Sacchi S., Federico M., Dastoli G., Fiorani C., Vinci G., Clò V., Casolari B.: Treatment of B-cell low-grade non-Hodgkin’s lymphoma with anti CD 20 monoclonal antibody RituximabCritical Reviews in Oncology-Hematology (ISSN 1040-8428) 37-13:25, 2001 395) Gobbi P.G., Zinzani P.L., Broglia C., Comelli M., Magagnoli M., Federico M., Merli F., Iannitto E., Tura S., Ascari E.: Comparison of prognostic models in patients with advanced Hodgkin disease. (Promising results from integration of the Best Three Systems). Cancer, 91:8,1467-1478,2001. 400) Guglielmi C., Martelli M., Federico M., Zinzani P.L., Vitolo U., Bellesi G., Santini G., Tarella C., Zallio F., Pregno P., Di Renzo N., Resegotti L.: Risk assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Haematologica 86:9,941-950, 2001 402) Sacchi S., Federico M., Vitolo U., Boccomini C., Vallisa D., Baldini L., Petrini M., Rupoli S., Di Raimondo F., Merli F., Liso V., Tabilio A., Saglio G., Vinci G., Brugiatelli M., Dastoli G. for GISL: Clinical activity and safety of combination immunotherapy with interferon-2a and rituximab in patients with relapsed low grade non-Hodgkin’s lymphoma. Haematologica 86:99,951-958,2001 426) Federico M., Zinzani P.L., Frassoldati A., Vinceti M., Modè A., Annino L., Chisesi T., Pagnucco 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 5 / 20 Curriculum Vitae Massimo Federico G., Invernizzi R., Spriano M., Resegotti L., Bendandi M., Damasio E. for the Italian Cooperative Group for the Study of Hairy Cell leukemia: Risk of second cancer in patients with hairy cell leukemia: longterm follow up. Journal of Clinical Oncology 20:39,638-646, 2002. 427) Chisesi T., Federico M., Levis A., Lambertenghi Deliliers G., Gobbi P.G., Santini G., Luminari S., Brugiatelli M.: ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s lymphoma: results of a randomised trial. Fifth International Symposium on Hodgkin’s Lymphoma, Cologne, Germany, 22-25 September 2002. Annals of Oncology 13:19,102-106, 2002. 428) Del Rio G., Zironi S., Valeriani L., Menozzi R., Bondi M., Bertolini M., Piccinini L., Banzi M.C., Federico M.: Weight gain in women with breast cancer treated with adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil. Analysis of resting energy expenditure and body composition. Breast Cancer Research and Treatment 73:267-273, 2002. 429) Turchetti D., Mangone L., Negri R., Rossi G., Cortesi L., Vinceti M., Maiorana A., Gallo E., Federico M.:Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of a mammographic screening program. Cancer Causes and Control, 13:729-734, 2002. 433) Morabito F., Baldini L., Stelitano C., Luminari S., Frassoldati A., Merli F., Colombi M., Sabbatini R., Brugiatelli M., Federico M., for the Gruppo Italiano per lo Studio dei Linfomi (GISL): Prospective study of indolent non-follicular non-Hodgkin’s lymphoma: validation of Gruppo Italiano per lo Studio dei Linfomi (GISL) prognostic criteria for watch and wait policy. Leukemia and Lymphoma, 43:10,1933-1938, 2002 443) Lombardo M., Morabito F., Merli F., Molica S., Cavanna L., Sacchi S., Broglia C., Angrilli F., Ilariucci F., Stelitano C., Luisi D., Berte’ R., Luminari S., Federico M., Brugiatelli M. for GISL: Bleomycin,Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in patients with follicular non-Hodgkin’s lymphoma: results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Leukemia and Lymphoma, 43:9,1795-1801, 2002. 444) Galimberti S., Marasca R., Caracciolo F., Fazzi R., Papineschi F., Benedetti E., Guerrini F., Morabito F., Oliva E., Di Renzo N., Federico M., Petrini M., Torelli G. for GISL: The role of molecular monitoring in autotransplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplantation, 29:581-587, 2002. 445) Zinzani P.L., Martelli M., Bertini M., Gianni A.M., Devizzi L., Federico M., Pangalis G., Michels J., Zucca E., Cantonetti M., Cortelazzo S., Wotherspoon A., Ferreri A.J.M., Zaja F., Lauria F., De Renzo A., Liberati M.A., Falini B., Balzarotti M., Calderoni A., Zaccaria A., Gentilini P., Fattori P.P., Pavone E., Angelopoulou M.K., Alinari L., Brugiatelli M., Di Renzo N., Bonifazi F., Pileri S.A., Cavalli F. for the International Extranodal Lymphoma Study Group (IELSG): Induction chemotherapy stategies for primary mediastinal large B-cell lmphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica, 87:12,1258-1264, 2002 446) Turchetti D., Cortesi L., Federico M., Romagnoli R., Silingardi V.: Hereditary risk of breast cancer: not only BRCA. Journal of Experimental Clinical Cancer Research, 21:3,17-21, 2002 448) Cortesi L., Canossi B., De Santis M., Panizza P., Rossi G., Turchetti D., Del Maschio A., Ferrarri S., Romagnoli R., Federico M., Silingardi V.: Usefulness of breast MRI in a patient with genetic risk. Journal of Experimental Clinical Cancer Research, 21:3,131-136, 2002 449) Baldini L., Brugiatelli M., Luminari S., Lombardo M., Merli F., Sacchi S., Gobbi P., Liberati M., Cavanna L., Colombi M., Stelitano C., Goldaniga M., Morabito F., Federico M., Silingardi V.: Treatment of indolent B-cell non-follicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Journal of Clinical Oncology, 21:8,1459-1465,2003 460) Cortesi L., Turchetti D., Bertoni C., Zanocco-Marani T., Vinceti M., Silvestri C., Federico M., Silingardi V. and Ferrari S.: Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes. European Journal of Human Genetics 11: 210-214, 2003 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 6 / 20 Curriculum Vitae Massimo Federico 462) Luminari S., Goldaniga M., Ceccherelli F., Guffanti A., Bombardieri E., Marcheselli R., Cro L., Colombi M., Federico M. and Baldini L.: Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. British Journal of Haematology 121:772-774, 2003 463) Federico M., Bellei M., Brice P., Brugiatelli M., Nagler A., Gisselbrecht C., Moretti L., Colombat Ph., Luminari S., Fabbiano F., Di Renzo N., Goldstone A., Carella A.M., on behalf of participants of EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial: High dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s Lymphoma responding front line therapy. Journal of Clinical Oncology, 21:12,2320-2325, 2003 464) Buiatti E., Barchielli A., Bartolacci S., Federico M., De Lisi V., Bucchi L., Ferretti S., Paci E., Segnan N., Tumino R. and the SCREENREG Working Group: The impact of organised Screening programmes on the stage-specific incidence of breast cancer in some Italian areas. Europen Journal of Cancer 39:1776-1782, 2003 465) Aretini P., D’Andrea E., Pasini B., Viel A., Mariani Costantini R., Cortesi L., Ricevuto E., Agata S., Bisegna R., Boiocchi M., Caligo M.A., Chieco-Bianchi L., Cipollini G., Crucianelli R., D’Amico C., Federico M., Ghimenti C., De Giacomi C., De Nicolo A., Della Puppa L., Ferrari S., Ficorella C., Iandolo D., Manoukian S., Marchetti P., Marroni F., Menin C., Montagna M., Ottini L., Pensotti V., Pierotti M., Radice P., Santarosa M., Silingardi V., Turchetti D., Bevilacqua G. and Presciuttini S.: Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedrigees with identified mutation. Breast Cancer Research and Treatment, 81:71-79, 2003 466) Franceschi S., Dal Maso L., Pezzotti P., Polesel J., Braga C., Piselli P., Serraino D., Tagliabue G., Federico M., Ferretti S., De Lisi V., La Rosa F., Conti E., Budroni M., Vicario G., Piffer S., Pannelli F., Giacomin A., Bellù F., Tumino R., Fusco M., Rezza G. for the Cancer and AIDS Registry Linkage Study: Incidence of AIDS-Defining cancers after AIDS Diagnosis among people with AIDS in Italy, 1986-1998 J Acquir Immune Defic Syndr, 34-1:84-90, 2003 469) Luminari S., Casolo A., De Santis M., Federico M.: Images in haematology, splenosis peritonei British Journal of Haematology, 123:378-378, 2003 470) Luminari S., Federico M., Baldini L.: Serum Muc-1 as a marker of disease status in multiple myeloma patients receiving Thalidomide – response to Mileshkin et al. British Journal of Haematology, 123:748-748, 2003 471) Gobbi P.G., Broglia C., Merli F., Dell’Olio M., Stelitano C., Iannitto E., Federico M., Luisi D., Molica S., Cavalli C., Dezza L., Ascari E.: Vinblastine, Bleomycin and Methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi. Cancer, 98-11:2393-401, 2003 472) Tarella C., Cuttica A., Vitolo U., Liberati M., Di Nicola M., Cortelazzo S., Rosato R., Rosanelli C., Di Renzo N., Musso M., Pavone E., Santini G., Pescarollo A., De Crescenzo A., Federico M., Gallamini A., Pregno P., Romano R., Coser P., Gallo E., Boccadoro M., Barbui T., Pileri A., Gianni A.M. and Levis A.: High-dose sequential chemotherapy and pheripheral blood progenitor cell (PBPC) autografting in refractory/relapsed Hodgkin’s limphoma: a multicenter study of Intergruppo Italiano Linfomi (I.I.L.) showing prolonged disease-free survival in patients treated at first relapse. Cancer, vol. 98-5: 2748-2759, 2003. 475) Rigacci L., Federico M., Martelli M., Zinzani P.L., Cavanna L., Bellesi G., Merli F., Alterini R., Petrucci M.T., Tani M., Liberati A.M., Vitolo U., Pavone V., Cuneo A., Chisesi T., Brugiatelli M.: The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leukemia and Lymphoma, 44-11:1911-1917, 2003 476) Gallamini A., Stelitano C., Calvi R., Bellei M., Mattei D., Vitolo U., Morabito F., Martelli M., Brusamolino E., Iannitto E., Zaja F., Cortelazzo S., Rigacci L., Devizzi L., Todeschini G., Santini G., Brugiatelli M., and Federico M. for the Intergruppo Italiano Linfomi: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood, 103-7:2474-2479, 2004 487) Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Crosignani P, Danzon A, Federico M, Gafa L, Grosclaude P, Hedelin G, Mace-Lesech J, Garcia CM, Moller H, Paci E, Raverdy N, Tretarre B, Williams EM: European Concerted Action on Survival and 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 7 / 20 Curriculum Vitae Massimo Federico Care of Cancer Patients (EUROCARE) WorkingGroup, Breast carcinoma survival in Europe and the United States. Cancer, 100:4-715:722, 2004. 490) Contegiacomo A, Pensabene M, Capuano I, Tauchmanova L, Federico M, Turchetti D, Cortesi L, Marchetti P, Ricevuto E, Cianci G, Venuta S, Barbieri V, Silingardi V.: An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol.15-5:726-32, may 2004. 491) Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, Mc Laughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E.: Follicular lymphoma international prognostic index. Blood, 104-5:1258-1265 2004 506) Ferreri A.J.M., Campo E., Ambrosetti A., Ilariucci F., Seymour J.F., Willemze R., Arrigoni G., Rossi G., Lopez-Guillermo A., Berti E., Erikson M., Federico M., Cortelazzo S., Govi S., Frungillo N., Dell’Oro S., Lestani M., Asioli S., Pedrinis E., Ungari M., Motta T., Rossi R., Artusi T., Iuzzolino P., Zucca E., Cavalli F., Ponzoni M., on behalf of the International Extranodal Lymphoma Study Group (IELSG): Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Annals of Oncology, 15:1215-1221, 2004 509) Merli F., Bertini M., Luminari S., Mozzana R., Bertè R., Trottini M., Stelitano C., Botto B., Pizzuti M., Quintana G., De Paoli A., Federico M.: Quality of live assessment in elderly patients with aggressive non-Hodgkin’s lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica, 89:973-978, 2004 511) Alemanni C., Sant M., Berrino F., Aareleid T., Chaplain G., Coebergh J.W., Colonna M., Costiero P., Danzon A., Federico M., Gafà L., Grosclaude P., Hedelin G., Macè-Lesech J., Garcia C.M., Paci E., Raverdy N., Tretarre B., and EMI Williams: Prognostic value of morphology and hormone receptor status in breast cancer – a population-based study. British Journal of Cancer, 91-1263:1268, 2004 515) Morabito F., Gallamini A., Stelitano C., Callea V., Guglielmi C., Neri S., Lazzaro A., Orsucci L., Ilariucci F., Sacchi S., Vitolo U. Federico M.: Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphoma unspecified and 496 diffuse B-cell lymphoma: the experience of the Intergruppo Italiano Linfoni (studio misto IIL/GISL) Cancer 101-7:1601-8, 2004 516) Bucchi L., Barchielli A., Ravaioli A., Federico M., De Lisi V., Ferretti S., Paci E., Vettorazzi M., Patriarca S., Frigerio A., Buiatti E., and the SCREENREG Working Group: Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size. British Journal of Cancer, 92-156:161, 2005 517) Dal Maso L., Polesel J., Ascoli V., Zambon P., Budroni M., Ferretti S., Tumino R., Tagliabue G., Patriarca S., Federico M., Vercelli M., Giacomin A., Vicario G., Bellù F., Falcini F., Crocetti E., De Lisi V., Vitarelli S., Piffer S., Stracci F., Serraino D., Rezza G., and Franceschi S., for the Cancer and AIDS Registry Linkage (CARL) Study: Classic Kaposi’s sarcoma in Italy, 1985-1998 British Journal of Cancer, 92-188:193, 2005 518) Rossi G., Valli R., Bertolini F., Marchioni A., Cavazza A., Mucciarini C., Migaldi M., Federico M., Trentini G.P., Sgambato A.: PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology, 46-522:531, 2005 519) Vitolo U., Liberati A.M., Cabras M.G., Federico M., Angelucci E., Baldini L., Boccomini C., Brugiatelli M., Calvi R., Ciccone G., Genua A., Lambertenghi Deliliers G., Levis A., Parvis G., Pavone E., Salvi F., Sborgia M., Gallo E. on behalf of The Intergruppo Italiano Linfomi: High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica, 90:6-793:801, 2005 524) Contegiacomo A., Pensabene M., Capuano I., Tauchmanova L., Federico M., Turchetti D., Cortesi L., Marchetti P., Ricevuto E., Cianci G., Barbieri V., Venuta S., Silingardi V.: Comment on 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 8 / 20 Curriculum Vitae Massimo Federico “Cancer genetic counselling” by P.Mandich et al. (Ann Oncol 2005, 16-171) Annals of Oncology, 16:7-1208-1209, 2005 526) Barchielli A., Federico M., De Lisi V., Bucchi L., Ferretti S., Paci E., Ponti., Buiatti E., for the Screenreg Working Group. In situ breast cancer: incidence trend and organised screening programmes in Italy. European Journal of Cancer, 41-7:1045-1050, 2005 527) Gobbi P.G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., Pavone V., Cavanna L., Santini G., Merli F., Liberati M., Baldini L., Lambertenghi Deliliers G., Angelucci E., Bordonaro R., Federico M.: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate–and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by Intergruppo Italiano Linfomi. Journal of Clinical Oncology, 23-36:9198-9207, 2005 528) Cortesi L., Chiuri V.E., Ruscelli S., Bellelli V., Negri R., Rashid I., Cirilli C., Fracca A., Gallo E., Federico M.: Prognosis of screen-detected breast cancer: results of a population based study. BMC Cancer, 6-17, 2006 529) Morabito F., Stelitano C., Luminari S., Mammi C., Marcheselli L., Callea V., Gentile M., Polimeno G., Merli F., Molica S., Gobbi P., Angrilli F., Brugiatelli M., Federico M.: The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodhkin’s lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplantation, 37:3-283-288, 2006 530) Federico M., Luminari S., Gobbi P.G., Sacchi S., Di Renzo N., Lombardo M., Merli F., Baldini L., Stelitano C., Partesotti G., Polimeno G., Montanini A., Mammi A., Brugiatelli M.: The length of treatment of aggressive non-Hodgkin’s lymphomas established according to the International Prognostic Index score: long-term results of the GISL LA03 study. European Journal of Haematology, 76:3-217-229, 2006 531) Di Renzo N., Brugiatelli M., Montanini A., Vigliotti M.L., Cervetti G., Liberati A.M., Luminari S., Spedini P., Giglio G., Federico M.: Vinorelbine, Gemcitabine, Procarbazine and Prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leukemia & Lymphoma, 47-3:473-479, 2006 532) Gobbi P.G., Broglia C., Levis A., La Sala A., Valentino F., Chisesi T., Sacchi S., Corbella F., Cavvanna L., Iannitto E., Pavone V., Molica S., Corazza G.R., Federico M.: MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin’s lymphoma: 10 year results, late toxicity and second tumors. Clinical Cancer Research, 12-2:529-535, 2006 533) Arcaini L., Lazzarino M., Colombo N., Burcheri S., Boveri E., Paulli M., Morra E., Gambacorta M., Cortelazzo S., Tucci A., Ungari M., Ambrosetti A., Menestrina F., Orsucci L., Novero D., Pulsoni A., Frezzato M., Gaidano G., Vallisa D., Minardi V., Tripodo C., Callea V., Baldini L., Merli F., Federico M., Franco V., Iannitto E.: Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 107-12:4643-4649, 2006 534) Gobbi P.G., Broglia C., Valentino F.,Mammi C., Lombardo M., Merli F., Luminari S., Polimeno G., Riezzo A., Lambelet P., Rovati A., Corazza G.R., Federico M.: The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) Annals of Oncology, 17:4-676:682, 2006-05-03 535) Luminari S., Federico M.: Prognosis of follicular lymphomas. Hematological Oncology, 24:64-72, 2006 536) Markman M., Federico M., Liu PY., Hannigan E., Alberts D.: Significance of early changes in the serum CA-125 antigen leve 1 on overall survival in advanced ovarian cancer. Gynecologic Oncology, 103:195-198, 2006 537) Marotta G., Frassoldati A., Zinzani P., Annino L., Brugiatelli M., Ambrosetti A., Lenoci M., Federico M., Foa R., Lauria F; the Italian Cooperative group for HCL (ICOHCL): Role of interferonalpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. European Journal of Haematology, 77-2:109-113, 2006 549) Agata S., Viel A., Della Puppa L., Cortesi L., Fersini G., Callegaro M., Dalla Palma M., Dolcetti R., 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 9 / 20 Curriculum Vitae Massimo Federico Federico M., Venuta S., Miolo G., D’Andrea E., Montagna M.: Prevalence of BRCA1 genomic rearrangements in a large cohort of italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. Genes, Chromosomes & Cancer, 45:791-797, 2006 550) Gobbi P.G., Levis A., Chisesi T., Pavone V., Federico M., Brugiatelli M., on behalf of the Intergruppo Italiano Linfomi: Unlike ABVD and MOPPEBVCAD, Stanford V chemotherapy does not tollerate the combination with a reduced and conditioned radiotherapy for the treatment of advanced Hodgkin Lymphoma The American Journal of Oncology Review, 5-6:356-359, 2006 552) Visco C., Nadali G., Vassilakopoulos TP., Bonfante V., Viviani S., Gianni AM., Federico M., Luminari S., Peethambaram P., Witzig TE., Pangalis G., Cabanillas F., Medeiros LJ., Sarris AH., Pizzolo G.: Very high levels of soluble CD30 recognize the patients with classical Hodgkin’s lymphoma retaining a very poor prognosis. European Journal of Haematology, 77:387-394, 2006 559) Cortesi L., Turchetti D., Marchi I., Fracca A., Canossi B., Battista R., Ruscelli S., Pecchi A.R., Torricelli P., Federico M.: Breast cancer screening in women at increased risk accordino to different family histories: an update of the Modena Study Group experience. BMC Cancer, 17:6-210, 2006 560) El Mistiri M., Verdecchia A.,Rashid I., El Sahli N., El Mangush M., Federico M.: Cancer incidence in eastern Libya: the first report the Benghazi Cancer Registry, 2003. Int. J. Cancer, 120:392-397, 2006 561) Luminari S., Federico M.: The role of anthracyclines in follicular lymphomas. (Editorial) Leukemia & Lymphoma, 47-11:2267-2268, 2006 562) Zorzi M., Puliti D., Vettorazzi M., De Lisi V., Falcini F., Federico M., Ferretti S., Moffa I.F., Mangone L., Mano M.P., Naldoni C., Ponti A., Traina A., Tumino R., Paci E. for the IMPACT Working Group: Mastectomy rates are decreasin in the era of service screening: a population-based study in Italy (1997-2001) British Journal of Cancer, 95:1265-1268, 2006-12-22 572) Merli F., Bertini M., Luminari S., Mozzana R., Botto B., Liberati A.M., Baldini L., Cabras G., Di Vito F., Orsucci L., Naglieri E., Polimeno G., Marcheselli L., Pennese E., Vitolo U., Federico M., Gallo E.: Long term results of a randomized study performed by Intergruppo Ialiano Linfomi comparing MiniCEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma, 48-2:367-373, 2007 573) Sardanelli F., Podo F., D’Agnolo G., Verdecchia A., Santaquilani M., Musumeci R., Trecate G., Manoukian S., Morassut S., de Giacomi C., Federico M., Cortesi L., Concione S., Cirillo S., Marra V., for the High Brest Cancer Risk Italian Trial (HIBCRIT): Multicenter comparative multimodality surveillance of women at genetic-familial risk for breast cancer (HIBCRIT study): interim results. Radiology, 242-3:698-715, 2007 579) Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., Coiffier B., Fisher R.I., Hagenbeck A., Zucca E., Rosen S.T., Stroobants S., Lister A., Hoppe R.T., Dreyling M., Tobinai K., Vose J.M., Connors J.M., Federico M., Diehl V.: Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25-5:579-586, 2007 580) Sacchi S., Pozzi S., Marcheselli FR., Federico M., Tucci A., Merli F., Orsucci L., Liberati M., Vallisa D., Brugiatelli M., on behalf of the Italian Lymphoma Study Group (GISL): Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer, 110:1-121:128, 2007 582) Federico M., Guglielmi C., Luminari S., Mammi C., Marcheselli L., Granelli U., Maiorana A., Merli F., Bellei M., Pozzi S., Stelitano C., Lazzaro A., Gobbi G.P., Baldini L., Bergantini S., Fregoni V., Brugiatelli M.: Prognostic relevance of serum beta-2 microglobulin in patients with follicular lymphoma treated with anthracycline containing regimens; a GISL study Haematologica, 92-11:1482-1488,2007 586) Rashid I., Marcheselli L., Federico M.: Estimating survival in newly diagnosed cancer patients: Use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 10 / 20 Curriculum Vitae Massimo Federico Statistics in Medicine,27:2145-2158,2008 590) Dal Maso L., Lise M., Zambon P., Crocetti E., Serraino D., Ricceri F., Vercelli M., De Lisi V., Tagliabue G., Federico M., Falcini F., Cassetti T., Donato A., Fusco M., Budroni M., Ferretti S., Tumino R., Piffer S., Bellù F., Mangone L., Giacomin A., Vitarelli S., Franceschi S.: Incidence of primary liver cancer in Italy between 1988 and 2002: an age-period-cohort analysis European Journal of Cancer, 44(2):285-292,2008 591) Luminari S., Cesaretti M., Rashid I., Mammi C., Montanini A., Barbolini E., Bellei M., Pennese E., Sirotti A.M., Marcheselli L., Partesotti G., Bari A., Maiorana A., Bonacorsi G., Federico M.: Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematological Oncology, 25:189-197,2007 592) Goldaniga M, Ferrario A, Cortelazzo S, Guffanti A, Pavone E, Ambrosetti A, Marcheselli L, Rossi F, Luminari S, Rossi A, Cro L, Federico M, Lambertenghi Deliliers G, Baldini L. : A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. Am J Hematol. 2008 May;83(5):349-54 593) Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A; Intergruppo Italiano Linfomi (IIL).: ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol. 2008 Apr;19(4):763-8. 598) Sacchi S., Marcheselli L., Bari A., Marcheselli R., Pozzi S., Gobbi PG:, Angrilli F., Brugiatelli M., Musto P., Federico M.: Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study. Haematologica, 2008 Sep;93(9):1335-42. Epub 2008 Aug 12. 599) Puliti D., Miccinesi G., Collina N., De Lisi V., Federico M., Ferretti S., Finarelli AC., Foca F., Mangone L., Naldoni C., Putrella M., Ponti A., Segnan N., Sigona A., Zarcone M., Zorzi M., Zappa M., Paci E., IMPACT Working Group: Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction. Br. J. Cancer, 99(3):423-7,2008 600) Neri A., Marmiroli S., Tassone P., Lombardi L., Nobili L., Verdelli D., Civallero M., Cosenza M., Bertacchini J., Federico M., De Pol A., Deliliers GL., Sacchi S.: The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leukemia & Lymphoma, 49(7):1374-83,2008 604) Federico M., Luminari S., Iannitto E., Polimeno G., Marcheselli L., Montanini A., La Sala A., Merli F., Stelitano C., Pozzi S., Scalone R., Di Renzo N., Musto P., Baldini L., Cervetti G., Angrilli F., Mazza P., Brugiatelli M., Gobbi P.G.: ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s Lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial J Clin Oncol (ISSN 0732-183X) 27:5-805:11, 2009 605) Dal Maso L., Polesel J., Serraino D., Lise M., Piselli P., Falcini F., Russo A., Intrieri T., Vercelli M., Zambon P., Tagliabue G., Zanetti R., Federico M., Limina RM., Mangone L., De Lisi V., Stracci F., Ferretti S., Piffer S., Budroni M., Donato A., Giacomin A., Bellù F., Fusco M., Madeddu A., Vitarelli S., Tessandori R., Tumino R., Suligoi B., Frances hi S. for the Cancer and AIDS Registries Linkage (CARL) Study: Pattern of cancer risk in persons with AIDS in Italy inthe HAART era. British Journal of Cancer, 100:840-847,2009 606) Gobbi G.P., Valentino F., Da nova M., Morabito F., Rovati B., Mammi C., Gentile M., Merli F., Stelitano C., Luminari S., Quintana G., Iannitto E., Brugiatelli M., Federico M.: Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin’s lymphoma. Oncology Reports, 21:1029-1035,2009-04-21 607) Carella A.M., Bellei M., Brice P., Gisselbrecht C., Visani G., Colombat P., Fabbiano F., Donelli A., Luminari S., Feugier P., Browett P., Hagberg H., Federico M.: High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long term results. Haematologica, 94(1).146-148,2009 608) Iannitto E., Minardi V., Gobbi P.G., Calvaruso G., Tripodo C., Marcheselli L., Luminari S., Merli F., 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 11 / 20 Curriculum Vitae Massimo Federico Baldini L., Stelitano C., Callea V., Petrini M., Angrilli F., Quarta G., Vallisa D., Molica s., Liardo E., Polimeno G., Brugiatelli M., Federico M.: Response-guided ABVD chemotherapy plus involved-field radiotherapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. Clinical Lymphoma & Myeloma, 9(2):138-144,2009 613) Federico M., Bellei M., Marcheselli L., Luminari S., Lopez-Guillermo A., Vitolo U., Pro B., Pileri S., Pulsoni A., Soubeyran P., Cortelazzo S., Martinelli G., Martelli M., Rigacci L., Arcaini L., Di Raimondo F., Merli F., Sabattini E., McLaughlin P., Solal-Céligny P.: Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project. Journal of Clinical Oncology, 1:9-4555:4562, 2009 617) Pecorari L., Marin O., Silvestri C., Candini O., Rossi E., Guerzoni C., Cattelani S., Mariani S.A., Corradini F., Ferrari-Amorotti G., Cortesi L., Bussolari R., Raschellà G., Federico M., Calabretta B.: Elongation factor I alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Molecular Cancer, 8-58, 2009 618) Luminari S., Cesaretti M., Marcheselli L., Rashid I., Madrigali S., Maiorana A., Federico M.: Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas Annals of Oncology (ISSN 0923-7534) 1:4-855:859, 2009 I.F. 4,93 619) Cortesi L., Barchetti A., De Matteis E., Rossi E., Della Casa L., Marcheselli L., Tazzioli G., Lazzaretti M.G., Ficarra G., Federico M., Iannone A.: Identification of protein clusters predictive of response to chemotherapy in breast cancer patients Journal of Proteome Research (ISSN 1535-3893) 8:11-4916:33, 2009 I.F. 5,68 624) Meignan M., Itti E., Bardet S., Lumbroso J., Edeline V., Oliver P., Borghi TV., Reman O., Karcher G., Mundler O., Mounier N., Ricci R., Federico M., Raemaekers J., Andrè M.: Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials Journal of Clinical Oncology (ISSN 0732-183X) 27:16-2739:2741, 2009 I.F. 15,48 626) Luminari S., Montanini A., Caballero D., Bologna S., Notter M., Dyer M.J.S., Chiappella A., Briones J., Petrini M., Barbato A., Kayitalire L., Federico M.: Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial Annals of Oncology (ISSN 0923-7534) 21:1-1492:1499, 2009 I.F. 4,93 627) Cortesi L., De Matteis E., Rashid I., Cirilli C., Proietto M., Rivasi F., Federico M.: Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study International Journal of Gynecological Cancer (ISSN 1048-891X) 19:8-1358:1363,2009 I.F. 1,93 628) Gobbi P.G., Rosti V., Valentino F., Bonetti E., Merli F., Stelitano C., Dondi A., Quarta G., Falorio S., Federico M.: The early- and intermediate- term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma Clinical Lymphoma & Myeloma (ISSN 1557-9190) 9:6-425:429, 2009 I.F. 1,59 631) Molica S., Di Raimondo F., Cutrona G., Fabris S., Mauro F., Brugiatelli M., Baldini L., Musto P., Sacchi S., Cortelezzi A., Foà R., Neri A., Federico M., Ferrarini M., Morabito F., on behalf of Gruppo Italiano Studio Linfomi (GISL): Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studi Linfomi (GISL) experience Leukemia Research (ISSN 0145-2126) 34:8-217:218, 2009 I.F. 2,39 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 12 / 20 Curriculum Vitae Massimo Federico 632) Allemani C., Storm H., Voogd A.C., Holli K., Izarzugaza I., Torrella-Ramos A., Bielska-Lasota M., Aareleid T., Ardanaz E., Colonna M., Crocetti E., Danzon A., Federico M., Garau I., Grosclaude P., Hèdelin G., Martinez-Garcia C., Peignaux K., Plesko I., Primic-Zakelj M., Rachtan J., Tagliabue G., Tumino R., Traina A., Tryggvadottir L., Vercelli M., Sant M.: Variation in “Standard care” for breast cancer across Europe: a EUROCARE-3 high resolution study European Journal of Cance (ISSN 0959-8049) 46:9-1528:1536, 2009 I.F. 4,47 633) Barrington S.F., Qian W., Somer E.J., Franceschetto A., Bagni B., Brun E., Almquist H., Loft A., Hojgaard L., Federico M., Gallamini A., Smith P., Johnson P., Radford J., O’Doherty M.J.: Concordance between four European centre of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma European Journal of Nuclear Medicine and Molecular Imaging (ISSN 1619-7070) 37:10-1824:1833, 2010 I.F. 4,53 634) Mannina D., Luminari S., Dondi A., Polimeno G., Baldini L., Stelitano C., Merli F., Dell’Olio M., Gobbi P.G., Giglio G., Barbolini E., Brugiatelli M., Federico M.: Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi Leukemia & Lymphoma (ISSN 1042-8194) 51:3-422:429, 2010 I.F. 2,49 635) Cortesi L., Masini C., Cirilli C., Medici V., Marchi I., Cavazzini G., Pasini G., Turchetti D., Federico M.: Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer (ISSN 1471-2407) 10:90, 2010 I.F. 2,74 636) Sardanelli F., Boetes B., Decker T., Federico M., Gilbert F.J., Helbich T., Heywang-Kobrunner S.H., Kaiser W.A., Kerin M.J., Mansel R.E., Marotti L., Martincich L., Mauriac L., Meijers-Heijboer H., Orecchia R., Panizza P., Ponti A., Purushotham A.D., Regitnig P., Rosselli Del Turco M., Thibaukt F., Wilson R.: Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group European Journal of Cancer (ISSN 0959-8049) 46:8-1296:1316, 2010 I.F. 4,12 637) El Mistiri M., Pirani M., El Sahli N., El Mangoush M., Attia A., Shembesh R., Habel S., El Homry F., Hamad S., Federico M.: Cancer profile in Eastern Libya: incidence and mortality in the year 2004 Annals of Oncology (ISSN 0923-7534) 21:9-1924:1926, 2010 I.F. 5,64 638) Federico M., Pirani M., Rashid I., Caranci N., Birilli C.: Cancer incidence in people with residential exposure to a municipal waste incinerator: an ecological study in Modena (Italy), 1991-2005 Waste Management (ISSN 0956-053X) 30:7-1362:1370, 2010 I.F. 2,43 639) Di Renzo N., Montanini A., Mannina D., Dondi A., Muci S., Mancuso S., De Polis M.R., Plati C., Stelitano C., Patti C., Olivieri A., Liardo E., Buda G., Cantaffa R., Federico M.: Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL) Support Care Cancer (ISSN 0941-4355) 19:10-1505:10, 2011 I.F. 2,08 640) Ferrario A., Merli F., Luminari S., Stelitano C., Mannina D., Russo M., Mazza P., Marcheselli L., Goldaniga M.,C., Federico M., Baldini L.: Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi Annals of Hematology (ISSN 0939-5555) 90:3-323:30, 2011 I.F. 2,91 641) Mian M., Marcheselli L., Luminari S., Federico M., Cantonetti M., Sarris A.H., Rossi A., Rambaldi A., Frontani M., Devizzi L., Gianni A.M., Busetto M., Berti E., Martinelli G., Tsang R.W., Ferreri A.J.M., 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 13 / 20 Curriculum Vitae Massimo Federico Pinotti G., Pugliani E., Zucca E., Cortelazzo S.: CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) Annals of Hematology (ISSN 0939-5555) 90:4-401:8, 2011 I.F. 2,91 649) Sardanelli F., Podo F., Santoro F., Manoukian S., Bergonzi S., Trecate G., Vergnaghi D., Federico M., Cortesi L., Corcione S., Morassut S., Di Maggio C., Cilotti A., Martincich L., Calabrese M., Zuiani C., Preda L., Bonanni B., Carbonaro LA., Contegiacomo A., Panizza P., Di Cesare E., Savarese A., Crecco M., Turchetti D., Tonutti M., Belli P., Maschio AD.: Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results High Breast Cancer Risk Italian 1 (HIBCRIT-1) Study, Invest Radiol (ISSN 0020-9996) 46:2-94:105, 2011 I.F. 4,85 650) Weisenburger DD., Savage KJ., Harris NL., Gascoyne RD., Jaffe ES., Maclennan KA., Rüdiger T., Pileri S., Nakamura S., Nathwani B., Campo E., Berger F., Coiffier B., Kim WS., Holte H., Federico M., Au WY., Tobinai K., Armitage JO., Vose JM.: Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project Blood (ISSN 0006-4971) 117:12-3402-3408, 2011 I.F. 10,55 651) Pirani M., Marcheselli R., Marcheselli L., Bari A., Federico M., Sacchi S.: Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis Ann Oncol (ISSN 0923-7534) 22:8-1845:1858, 2011 I.F. 5,64 652) Mian M., Gaidano G., Conconi A., Tsang R., Gospodarowicz MK., Rambaldi A., Rossi A., Oldani E., Federico M., Luminari S., Bellei M., Pogliani EM., Rossini F., Cabrera ME., Martelli M., LopezGuillermo A., Busetto M., Cavalli F., Zucca E., Cortelazzo S. : High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study Leukemia & Lymphoma (ISSN 1042-8194) 52:5-823:832, 2011 I.F. 2,49 653) Delabie J., Holte H., Vose JM., Ullrich F., Jaffe ES., Savage KJ., Connors JM., Rimsza L., Harris NL., Muller-Hermelink K., Rudiger T., Coiffier B., Gascoyne RD., Berger F., Tobinai K., Au WY., Liang R., Montserrat E., Hochberg EP., Pileri S., Federico M., Nathwani B., Armitage JO., Weisenburger DD.: Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project Blood (ISSN 0006-4971) 118:1-148:155, 2011 I.F. 10,55 654) Gobbi PG., Federico M.: What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma? Critical Reviews in Oncology Hematology (ISSN 1040-8428) 82:1-18:24, 2011 I.F. 5,26 656) Gobbi PG., Valentino F., Bassi E., Coriani C., Merli F., Bonfante V., Marchianò A., Gallamini A., Bolis S., Stelitano C., Levis A., Federico M., Angrilli F., Di Giulio G., Corazza GR.: Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin Lymphoma Clin Lymphoma Myeloma Leuk (ISSN 2152-2650) 11:5-396:402, 2011 I.F. 1,98 657) Cortesi L., Rossi E., Della Casa L., Barchetti A., Nicoli A., Piana S., Abrate M., La Sala GB., Federico M., Iannone A.: Protein expression patterns associated with advanced stage ovarian cancer Electrophoresis (ISSN 0173-0835) 32:15-1992:-2003, 2011 I.F. 3,56 658) Luminari S., Cesaretti M., Tomasello C., Guida A., Bagni B., Merli F., Postiglione r., Mangone L., Versari A., Re F., De Lisi V., Ruffini L., Ferretti S., Cuneo A., Federico M.: Use of 2-[18F]fluoro-2deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 14 / 20 Curriculum Vitae Massimo Federico population-based study from Northern Italy Leukemia & Lymphoma (ISSN 1042-8194) 52:9-1689:1696, 2011 I.F. 2,49 659) Maura F., Cutrona G., Fabris S., Colombo M., Tuana G., Agnelli L., Matis S., Lionetti M., Gentile M., Recchia A.G., Di Raimondo F., Musolino C., Ilariucci F., Di Renzo N., Pesce E., Molica S., Federico M., Cortelezzi A., Morabito F., Ferrarini M., Neri A.: Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia PLoS One (ISSN 1932-6203) 6:8-e24313, 2011 I.F. 4,4 660) Chisesi T., Bellei M., Luminari S., Montanini A., Marcheselli L., Levis A., Gobbi P.G., Vitolo U., Stelitano C., Pavone V., Merli F., Liberati M., Baldini L., Bordonaro R., Pesce E.A., Federico M.: Longterm follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versusu MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. Journal of Clinical Oncology (ISSN 0732-183X) 29:32-4227:4233, 2011 I.F. 18,97 664) Merli F., Luminari S., Rossi G., Mammi C., Marcheselli L., Tucci A., Ilariucci F., Chiappella A., Musso M., Di Rocco A., Stelitano C., Alvarez I., Baldini L., Mazza P., Salvi F., Arcari A., Fragasso A., Gobbi P.G., Liberati A.M., Federico M.: R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL) Leukemia & Lymphoma (ISSN 1042-8194) 53:4-581:588, 2012 I.F. 2,30 665) Morabito F., Hohaus S., Mammi C.,Marcheselli L., Gentile M., Merli F., Montanini A., Stelitano C., La Salal A., Scalone R., Voso M.T., Luminari S., Iannitto E., Gobbi P.G., Federico M.: Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial Leukemia & Lymphoma (ISSN 1042-8194) 53:3-406:410, 2012 I.F. 2,30 666) Merli F., Luminari S., Ilariucci F., Petrini M., Visco C., Ambrosetti A., Stelitano C., Caracciolo F., Di Renzo N., Angrilli F., Carella A.M., Capodanno I., Barbolini E., Galimberti S., Federico M.: Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial tretment of patients with mantle cell lymphoma: a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol (ISSN 1365-2141 ) 156:3-346:353, 2012 I.F. 4,9 667) Joensuu H., Vehtari A., Riihimaki J., Nishida T., Steigen S.E., Brabec P., Plank L., Nilsson B., Cirilli C., Braconi C., Magnusson M.K., Linke Z., Sufliarsky J., Federico M., Jonasson J.G., Dei Tos A.P., Rutkowski P.,: Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol (ISSN 1470-2045) 13:3-265:274, 2012 I.F. 17,7 668) Gobbi P.G., Bassi E., Bergonzi M., Merli F., Coriani C., Iannitto E., Luminari S., Polimeno G., Federico M.:Tumor burden predicts treatment resistance in patients with early unfavourable or advanced Hodgkin lymphoma treated with ABVD and radiotherapy. Hematological Oncology (ISSN 0278-0232) 30:4-194:199, 2012 I.F. 2,2 674) Cortesi L, Proietto M., Cirilli C., Tazzioli G., Andreotti A., Federico M.: Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. J Surg Oncol (ISSN 0022-4790) 106:4-399:404, 2012 I.F. 2,42 675) Cortesi L., De Nicolo A., Medici V., Marino M., Turchetti D., Pradella LM., Rossi G., Parisini E., Federico M.: Collective evidence supports neutrality of BRCA1 v1687i, a novel sequence variant in the conserved THV motif of the first BRCT repeat. 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 15 / 20 Curriculum Vitae Massimo Federico Breast Cancer Res Treat (ISSN 0167-6806) 134:1-435:441, 2012 I.F. 4,85 676) Federico M., Rudiger T., Bellei M., Nathwani BN., Luminari S., Coiffier B., Harris NL., Jaffe E., Pileri S., Savane KJ., Weisenburger DD., Armitage JO., Mounier N., Vose Jm.: Clinicopathologic characteristics of angioimmunoblastics T-cell lymphoma (AITL): analysis of 243 cases from the International Peripheral T-cell Lymphoma Project Journal of Clinical Oncology (ISSN 0732-183X) 31:2-240:246, 2013 I.F. 18,97 677) Solal-Céligny P., Bellei M., Marcheselli L., Pesce,E.A., Pileri S., McLaughlin P., Luminari S., Pro B., Montoto S., Ferreri A.J.M., Deconinck E., Milpied N., Gordon L.I., Federico M.: Watchful Waiting In Low-Tumor Burden Follicular Lymphoma In The Rituximab Era. Results Of A F2 Observational Study Journal of Clinical Oncology (ISSN 0732-183X) 30:31-3848:3853, 2012 I.F. 18,97 679) Gobbi P.G., Bergonzi M., Bassi E., Merli F., Coriani C., Stelitano C., Iannitto E., Federico M.: Tumor burden in Hodgkin’s lymphoma can be reliably estimated from a few staging parameters. Oncology Reports (ISSN 1021-335X) 28:3-815:820, 2012 I.F. 1,83 681) Carella AM; De Souza C., Luminari S., Marcheselli L., Chiappella A., Di Rocco A., Cesaretti M., Rossi A., Rigacci L., Gaidano G., Merli F., Spina M., Stelitano C., Hohaus S., Barbui A., Puccini B., Mirando E., Guida A., Federico M.: Prognostic role of gender in diffuse large B-cell lymphoma treated with Rituximab containing regimens: a FIL/GEMOH retrospective study. Leukemia & Lymphoma (ISSN 1042-8194) 54:1-53:57, 2013 I.F. 2,30 682) Sant M., Minicozzi P., Allemani C., Cirilli C., Federico M., Capocaccia R., Budroni M., Candela P., Crocetti E., Falcini F., Ferretti S., Fusco M., Giacomin A., La Rosa F., Mangone L., Natali M., Leon MP., Traina A., Tumino R., Zambon P.: Regional inequalities in cancer care persist in Italy and can influence survival. Cancer Epidemiology (ISSN 1877-7821) 36:6-541:547, 2012 I.F. 2,01 683) Mian M., Ferreri AJ., Rossi A., Conconi A., Tsang R., Gospodarowicz MK., Oldani E., Federico M., Luminari S., Pogliani EM., Rossigni F., Cabrera ME., Martelli M., Gutierrez-Garcia G., Busetto M., Cavalli F., Zucca E., Rambaldi A., Cortelazzo S., on behalf of the International Extranodal Lymphoma Study Group (I.E.L.S.G.): The role of radiotherapy in patients with early-stage diffuse large B-cell lymphomas of the Waldeyer’s ring in remission after anthracycline-containing chemotherapy. Leukemia & Lymphoma (ISSN 1042-8194) 54:1-62:68, 2013 I.F. 2,30 685) Cortesi L., Marcheselli L., Guarneri V., Cirilli C., Braghiroli B., Toss A., Sant M., Ficarra G., Conte P.F., Federico M.: Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. International Journal of Cancer (ISSN 0020-7136) 132:2-E58:65, 2013 I.F. 5,44 687) Falorio S., Biasoli I., Luminari S., Quintana G., Musso M., Dell’Olio M., Specchia M.R., Di Renzo N., Cesaretti M., Buda G., Vallisa D., Mannina D., Andriani A., Chiattone C.S., Delamain M.T., De Souza C.A., Spector N., Angrilli F., Federico M.: Risk factor for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from italian and brazilian institutions. Hematological Oncology (ISSN 0278-0232) 31:2-332:338, 2012 I.F. 2,03 688) Ghielmini M., Vitolo U., Kimby E., Montoto S., Walewski J., Pfreundschuh M., Federico M., Hoskin P., McNamara C., Caligaris-Cappio F., Stilgenbauer S., Marcus R., Trneny M., Dreger P., Montserrat E., Dreyling M., on behalf of the Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma: ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 16 / 20 Curriculum Vitae Massimo Federico lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology (ISSN 0923-7534) 24:3-561:576, 2013 I.F. 6,42 690) Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., Neri A., Federico M., Ferrarini M., Morabito F.: External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer (ISSN 0008-543X) 119:6-1177:1185, 2013 I.F. 4,77 693) Bari A., Tadmor T., Sacchi S., Marcheselli L., Liardo E.V., Pozzi S., Luminari S., Baldini L., Marmiroli S., Federico M., Polliack A.: Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas Leukemia Research (ISNN 0145-2126) 37:6-619:623, 2013 I.F. 2,92 694) Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., Neri A., Federico M., Ferrarini M., Morabito F.: The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis Leukemia Research (ISNN 0145-2126) 37:8-943:947, 2013 I.F. 2,92 695) Merli F., Luminari S., Rossi G., Mammi C., Marcheselli L., Ferrari A., Spina M., Tucci A., Stelitano C., Capodanno I., Fragasso A., Baldini L., Bottelli C., Montechiarello E., Fogazzi S., Lamorgesse C., Cavalli L., Federico M.: Outcome of frail of elderly patients with diffuse large B-cell lymphoma (DLBCL) prospectively identified by comprehensive geriatric assessment (CGA). Results from a study of the Fondazione Italiana Linfomi (FIL). Leukemia & Lymphoma (ISSN 1042-8194), 55:1-38:43, 2014 I.F. 2,30 696) Federico M., Luminari S., Dondi A., Tucci A., Vitolo U., Rigacci L., Di Raimondo F., Carella A.M., Pulsoni A., Merli F., Arcaini L., Angrilli F., Stelitano C., Gaidano G., Dell’Olio M., Marcheselli L., Franco V., Galimberti S., Sacchi S., Brugiatelli M .: R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology (ISSN 0732-183X) 31:12-1506:1513, 2013 I.F. 18,97 697) Gentile M., Cutrona G., Fabris S., Pesce E.A., Baldini L., Di Raimondo F., Musolino C., Di Tonno P., Di Renzo N., Molica S., Brugiatelli M., Ilariucci F., Zupo S., Matias S., Maura F., Vigna E., Angrilli F., Recchia A.G., Quarta G., Iannitto E., Fragasso A., Musto P., Spriano M., Vincelli I., Vallisa D., Cortelezzi A., Mauro F.R., Foà R., Federico M., Neri A., Ferrarini M., Morabito F.: Total body computer tomography scan in the initial work-up of binet stage a chronic lymphocytic leukemia patients: results of the prospective, multicenter o-cll1-gisl study American Journal of Hematology (ISNN 0361-8609) 88:7-539:544, 2013 I.F. 4,13 698) Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri A.J., Zinzani P.L., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella A.M., Santoro A., Musto P., Federico M.: The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi Annals of Oncology (ISSN 0923-7534) 24:8-2108-2112, 2013 I.F. 6,42 699) Toss A., De Matteis E., Rossi E., Della Casa L., Iannone A., Federico M., Cortesi L.: Ovarian cancer: can proteomics give new insights for therapy and diagnosis? International Journal of Molecolar Sciences (ISNN 1661-6596) 14:4-8271:8290, 2013 I.F. 2,59 700) Bella F., Minicozzi P., Giacomin A., Crocetti E., Federico M., Ponz de Leon M., Fusco M., Tumino R., Mangone L., Giuliani O., Budroni M., Sant M.: Impact of diabetes on overall and cancer-specific mortalità in colorectal cancer patients. 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 17 / 20 Curriculum Vitae Massimo Federico Journal of Cancer Research and Clinical Oncology (ISNN 0171-5216) 139:8-1303:1310, 2013 I.F. 2,55 707) Zucchetto A., Ronco G., Rossi P.G., Zappa M., Ferretti S., Franzo A., Falcini F., Visioli G.B., Zanetti R., Biavati P., La Rosa F., Baracco S., Federico M., Campari C., De Togni A., Piffer S., Pannozzo F., Fusco M., Michiara M., Castaing M., Seghini P., Tisano F., Serraino D.: Screening patterns within organized programs and survival of italian women with invasive cervical cancer Preventive Medicine (ISNN 0091-7435) 57:3-220:226, 2013 I.F. 3,49 711) Piccaluga P.P., Fuligni F., De Leo A., Bertuzzi C., Rossi M., Bacci F., Sabattini E., Agostinelli C., Gazzola A., Laginestra M.A., Mannu C., Sapienza M.R., Hartmann S., Hansmann M.L., Piva R., Iqbal J., Chan J.C., Weisenburger D., Vose J.M., Bellei M., Federico M., Inghirami G., Zinzani P.L., Pileri S.A.: Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study Journal of Clinical Oncology (ISSN 0732-183X) 31:24-3019:3025, 2013 I.F. 18,97 712) Zaja F., Federico M., Vitolo U., Zinzani P.L.: Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies Leukemia & Lymphoma (ISSN 1042-8194) 55:5-988.998, 2013 I.F. 2,30 713) Pozzi S.,. Marcheselli L., Bari A., Liardo E.V., Marcheselli R., Luminari S., Quaresima M., Cirilli C., Ferri P., Federico M., Sacchi S.: Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis British Journal of Haematology (ISNN 0007-1048 ) 163:1-40:46, 2013 I.F. 4,94 714) Minicozzi P., Bella F., Toss A., Giacomin A., Fusco M., Zarcone M., Tumino R., Falcini F., Cesaraccio R., Candela G., La Rosa F., Federico M., Sant M.: Relative and disease-free survival for breast cancer in relation to subtype: a population-based study Journal of Cancer Research and Clinical Oncology (ISNN 0171-5216) 139:9-1569:1577, 2013 I.F. 2,91 715) Tadmor T., Bari A., Sacchi S., Marcheselli L., Liardo E.V., Avivi I., Beniamini N., Attias D., Pozzi S., Cox M.C., Baldini L., Brugiatelli M., Federico M., Polliack A.: Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era Haematologica (ISNN 0390-6078), 99:1-125:30, 2014 I.F. 5.93 716) Mian M., Capello D., Ventre M.B., Grazio D., Svaldi M., Rossi A., Tsang R., Gospodarowicz M.K., Oldani E., Federico M., Luminari S., Marcheselli L., Pogliani E.M., Rossigni F., Cabrera M.E., Martelli M., Gutierrez-Garcia G., Busetto M., Visco C., Fiegl M., Rossi D., Gaidano G., Cavalli F., Zucca E., Rambaldi A., Cortelazzo S.: Early-stage diffuse large B cell lymphoma of the head and neck: clinicobiological characterization and 18 year follow-up of 488 patients (IESLG 23 study) Annals of Hematology (ISSN 0939-5555), 2013 Published online August 20, 2013 I.F. 2,86 718) Colaci M., Giuggioli D., Vacchi C., Lumetti F., Iachetta F., Marcheselli L., Federico M., Ferri C.: Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmunity Reviews (ISNN 1568-9972) 13:2-132:137, 2013 I.F. 7,97 719) Pashaj E., Cortesi L., Proietto M., Bonacorsi G., Liardo E., Federico M.: A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate. Future Oncology (ISNN1479-6694) 9:10-1437:1442, 2013 I.F. 3,20 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 18 / 20 Curriculum Vitae Massimo Federico 721) Federico M., Bellei M., Cheson B.D.: BEACOPP or no BEACOPP Lancet Oncol. (ISNN 1470-2045) 14:12-e487:e488, 2013 I.F. 14,47 724) Cortesi L., Razzaboni E., Toss A., De Matteis E., Marchi I., Medici V., Tazzioli G., Andreotti A., De Santis G., Pignatti M., Federico M.: A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women. Annals of Oncology (ISSN 0923-7534) 25:1-57:63, 2014 I.F. 6,42 725) Luminari S., Biasoli I., Versari A., Rattotti S., Battelli C., Rusconi C., Merli F., Spina M., Ferreri A.J., Zinzani P.L., Gallamini A., Franceschetto A., Boccomini C., Franceschetti S., Salvi F., Raimondo F.D., Carella A.M., Quaresima M., Balzarotti M., Musto P., Federico M.: The prognostic role of postinduction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Annali of Oncology (ISSN 0923-7534) 25:2-442:447, 2014 I.F. 6,42 726) Raemaekers J.M.M., Andrè M.P.E., Federico M., Girinsky T., Oumedaly R., Brusamolino E., Brice P., Fermè C., van der Maazen R., Gotti M., Bouabdallah R., Sebban C.J., Lievens Y., Re A., Stamatoullas A., Morschhauser F., Lugtenburg P.J., Abruzzese E., Olivier P., Casasnovas R.O., van Imhoff G., Raveloarivahy T., Bellei M., van der Borght T., Bardet S., Versari A., Hutchings M., Meignan M., Fortpied C.: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associadet with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial Journal of Clinical Oncology (ISSN 0732-183X) 32:12-1188:94, 2014 I.F. 18,97 727) Zinzani P.L., Federico M., Oliva S., Pinto A., Rigacci L., Specchia G., Tucci A., Vitolo U.: The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodsgkin lymphoma. Leukemia & Lymphoma (ISSN 1042-8194), 2014 Published online March 24, 2014 I.F. 2,30 728) Gentile M., Cutrona G., Mosca L., Matis S., Fabris S., Lionetti M., Ilariucci F., Zupo S., Musolino C., Levato L., Molica S., Di Raimondo F., Vincelli I., Di Renzo N., Pesce E.A., Angrilli F., Federico M., Neri A., Ferrarini M., Morabito F.: Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL 1-GISL study American Journal of Hematology (ISNN 0361-8609), 2014 Published online April 8, 2014 I.F. 4,13 729) Biasoli I., Cesaretti M., Bellei M., Maiorana A., Bonacorsi G., Quaresima M., Salati M., Federico M., Luminari S.: Dismal outcomem of t-call lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry Hematological Oncology (ISSN 0278-0232), 2014 Published online April 29, 2014 I.F. 2,03 730) Bari A., Tadmor T., Sacchi S., Marcheselli L., Cox C., Liardo E.V., Pozzi S., Beniamini N., Avivi I., Ferrari A., Baldini L., Falorio S., Gobbi P., Federico M., Polliack A.: Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy British Journal of Haematology (ISNN 0007-1048 ), 2014 Published online May 3, 2014 I.F. 4,94 Projects 24/5/14 He was a member of the executive committee of the International Follicular Lymphoma Prognostic Factor Project (FLIPI), launched in 2000 by Dr Philippe Solal-Celigny in Le Mans, France. In 2003, as a further development of the FLIPI consortium, professor Federico launched the idea of prospective © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 19 / 20 Curriculum Vitae Massimo Federico collect clinical and biological data to investigate prognosis in patients with FL. The FLIPI2 study was commenced and collected more than 1,000 cases of FL in 2 years. The final results were published in 2009 on JCO. Following the conclusion of the FLIPI2 study, a similar project was also proposed for T Cell Lymphoma. Thus the T Cell Project was launched, allowing the collection of more than 1200 cases of PTCL collected so far. The final results of this study will be presented once again in Lugano, at the 13th International Conference on Malignant Lymphoma scheduled for June 2015. Memberships - Italian Society of Haematology - Italian Society of Medical Oncology - Italian Society of Cancerology - American Society of Clinical Oncology - American Society of Hematology - European Society of Medical Oncology - International Association of Cancer Registry Other Relevant Information In 1994 Professor Federico launched a fundraising campaign to create a new cancer center in Modena. The camapign was successful and in December 2001 the center opened to patients. AWARDS 1989 "NATO Senior Fellowships" grant from CNR (Italian Council of Research) 1993 Grant from Italian Foundation for Cancer Research 1994 Grant from National Cancer Institute of Bethesda, Maryland 1995 Agreement as “Assistant Research Scientist” at University of Arizona 1999 “Terra del Sole” Award from Premio Barocco Committee, Gallipoli (LE) 2003 “Mediterraneo” Award, Gallipoli (LE) 2003 “Mancaversa in fiore” Award, Taviano (LE) 2006 Silver Plate from “Provincia di Salerno” 2007 Scientific Research Award, 2007 – AIL Salerno 2008 “La Lampada di Aladino” Award, Brugherio (MI) 2008 “La Torre” Award, Città di Racale (LE) 2009 “Modenese dell’anno”, Award Modena Qui, S.Cesario s/Panaro (MO) 2010 “Ottaviano 2010” Award, Taviano (LE) 2010 Guido Di Domenico, Award Cava dé Tirreni (SA) 2011 “Melvin Jones Fellow”, Lions Club Award, Taviano (LE) 2011 “Kallistos Award - a life for research” , Mancaversa-Taviano (LE) 2012 Premio 3° Memorial Dott. Renato Marzano, Racale (LE) 24/5/14 © European Union, 2002-2014 | http://europass.cedefop.europa.eu Page 20 / 20
© Copyright 2024 Paperzz